Keigo Saito

Title: Innovations of Keigo Saito in Cancer Immunotherapy

Introduction

Keigo Saito is a prominent inventor based in Chiba, Japan, known for his significant contributions to the field of cancer immunotherapy. With a total of four patents to his name, Saito has focused on developing innovative antibodies that target specific cancer markers.

Latest Patents

One of Saito's latest patents is the Anti-GPC3 antibody. This invention aims to provide an anti-GPC3 antibody that recognizes an epitope different from existing antibodies, such as GC33 and GC199. The antibody can specifically bind to GPC3 localized on a cell membrane, even in the form of a single chain antibody. Additionally, the patent includes a CAR (Chimeric Antigen Receptor) comprising the anti-GPC3 single chain antibody, an immunocompetent cell expressing the CAR, and methods for specifically detecting GPC3. This innovation is particularly useful for cancer immunotherapy, as CAR-immunocompetent cells prepared based on this single chain antibody can effectively target cancer cells.

Career Highlights

Throughout his career, Keigo Saito has worked with esteemed institutions such as the National Cancer Center and Yamaguchi University. His work has significantly advanced the understanding and treatment of cancer through innovative antibody development.

Collaborations

Saito has collaborated with notable colleagues, including Tetsuya Nakatsura and Koji Tamada, to further enhance his research and innovations in the field.

Conclusion

Keigo Saito's contributions to cancer immunotherapy through his innovative patents and collaborations highlight his role as a leading inventor in the medical field. His work continues to pave the way for advancements in cancer treatment.